117 related articles for article (PubMed ID: 27494930)
21. Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial.
Galli L; Spagnuolo V; Bigoloni A; D'Arminio Monforte A; Montella F; Antinori A; Di Biagio A; Rusconi S; Guaraldi G; Di Giambenedetto S; Borderi M; Gibellini D; Caramatti G; Lazzarin A; Castagna A;
J Antimicrob Chemother; 2016 Jun; 71(6):1637-42. PubMed ID: 26945711
[TBL] [Abstract][Full Text] [Related]
22. Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial.
Pérez-Valero I; Pasquau J; Rubio R; Rivero A; Santos J; Sanz J; Mariño A; Crespo M; Hernández-Quero J; Iribarren JA; Gutiérrez F; Terrón A; Esteban H; Pérez-Molina JA;
J Antimicrob Chemother; 2018 Sep; 73(9):2444-2451. PubMed ID: 29897573
[TBL] [Abstract][Full Text] [Related]
23. Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient.
Lanzafame M; Lattuada E; Nicolè S; Rigo F; Cucchetto G; Concia E; Vento S
Int J STD AIDS; 2017 Jun; 28(7):726-728. PubMed ID: 27789848
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
[TBL] [Abstract][Full Text] [Related]
25. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
Squires KE; Young B; Dejesus E; Bellos N; Murphy D; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
AIDS; 2010 Aug; 24(13):2019-27. PubMed ID: 20613461
[TBL] [Abstract][Full Text] [Related]
26. Atazanavir exposure is effective during pregnancy regardless of tenofovir use.
Colbers A; Hawkins D; Hidalgo-Tenorio C; van der Ende M; Gingelmaier A; Weizsäcker K; Kabeya K; Taylor G; Rockstroh J; Lambert J; Moltó J; Wyen C; Sadiq ST; Ivanovic J; Giaquinto C; Burger D;
Antivir Ther; 2015; 20(1):57-64. PubMed ID: 24992294
[TBL] [Abstract][Full Text] [Related]
27. Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir/ritonavir monotherapy versus triple therapy in the MONET trial.
Geretti AM; Arribas JR; Lathouwers E; Foster GM; Yakoob R; Kinloch S; Hill A; van Delft Y; Moecklinghoff C
HIV Clin Trials; 2013; 14(1):45-50. PubMed ID: 23372114
[TBL] [Abstract][Full Text] [Related]
28. Occurrence of selective ritonavir nonadherence and dose-staggering in recipients of boosted HIV-1 protease inhibitor therapy.
Shuter J; Sarlo JA; Rode RA; Zingman BS
HIV Clin Trials; 2009; 10(3):135-42. PubMed ID: 19632952
[TBL] [Abstract][Full Text] [Related]
29. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
[TBL] [Abstract][Full Text] [Related]
30. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
Eron J; Yeni P; Gathe J; Estrada V; DeJesus E; Staszewski S; Lackey P; Katlama C; Young B; Yau L; Sutherland-Phillips D; Wannamaker P; Vavro C; Patel L; Yeo J; Shaefer M;
Lancet; 2006 Aug; 368(9534):476-82. PubMed ID: 16890834
[TBL] [Abstract][Full Text] [Related]
31. [Atazanavir-induced nephrolithiasis].
Valencia ME; Moreno V
Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):134-5. PubMed ID: 19246127
[No Abstract] [Full Text] [Related]
32. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
Kempf DJ; King MS; Bernstein B; Cernohous P; Bauer E; Moseley J; Gu K; Hsu A; Brun S; Sun E
J Infect Dis; 2004 Jan; 189(1):51-60. PubMed ID: 14702153
[TBL] [Abstract][Full Text] [Related]
33. Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons.
Bartlett JA; Miralles GD; Sevin AD; Silberman M; Pruitt SK; Ottinger J; Gryszowska V; Fiscus SA; Bucy RP;
AIDS Res Hum Retroviruses; 2002 May; 18(8):535-43. PubMed ID: 12036483
[TBL] [Abstract][Full Text] [Related]
34. Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimen.
Loutfy MR; Ackad N; Antoniou T; Baril JG; Conway B; de Wet J; Trottier B; Kovacs CM; Thompson W; Martel AY; Trottier S; Rouleau D; Shafran SD; Rachlis A; Fraser C; Smaill F; Walmsley SL; Tseng AL; Sampalis JS
HIV Clin Trials; 2007; 8(5):259-68. PubMed ID: 17956827
[TBL] [Abstract][Full Text] [Related]
35. PI monotherapy effective as maintenance.
AIDS Patient Care STDS; 2005 Oct; 19(10):696. PubMed ID: 16232054
[No Abstract] [Full Text] [Related]
36. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.
Arribas JR; Girard PM; Landman R; Pich J; Mallolas J; Martínez-Rebollar M; Zamora FX; Estrada V; Crespo M; Podzamczer D; Portilla J; Dronda F; Iribarren JA; Domingo P; Pulido F; Montero M; Knobel H; Cabié A; Weiss L; Gatell JM;
Lancet Infect Dis; 2015 Jul; 15(7):785-92. PubMed ID: 26062880
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
Slama L; Landman R; Assoumou L; Benalycherif A; Samri A; Joly V; Pialoux G; Valin N; Cabié A; Duvivier C; Lambert-Niclot S; Marcelin AG; Peytavin G; Costagliola D; Girard PM;
J Antimicrob Chemother; 2016 Aug; 71(8):2252-61. PubMed ID: 27068399
[TBL] [Abstract][Full Text] [Related]
38. Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study.
Santoro MM; Bertoli A; Lorenzini P; Lazzarin A; Esposito R; Carosi G; Di Perri G; Filice G; Moroni M; Rizzardini G; Caramello P; Maserati R; Narciso P; Cargnel A; Antinori A; Perno CF;
AIDS Patient Care STDS; 2008 Jan; 22(1):7-16. PubMed ID: 18095835
[TBL] [Abstract][Full Text] [Related]
39. Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients.
Tremblay C; Trottier B; Rachlis A; Baril JG; Loutfy M; Lalonde R; Sampalis JS; Boulerice F
HIV Clin Trials; 2011; 12(3):151-60. PubMed ID: 21684855
[TBL] [Abstract][Full Text] [Related]
40. Alteration of complement protein levels after antiretroviral therapy in HIV-infected persons.
Spear GT; Olinger G; Sullivan BL; Landay AL; Kessler H; Connick E; Kuritzkes D; St Clair M; Spritzler J; Wu H; Lederman MM
AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1713-5. PubMed ID: 10606095
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]